A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds
Launched by CONVATEC INC. · Nov 18, 2022
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
A prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, performance and safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of surgical and traumatic wounds for up to 4 weeks
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 years and over
- • Patients able and willing to provide informed consent
- • Patients with Surgical wounds including incisional wounds including laparoscopic
- • wounds and surgical wounds healing by secondary intention.
- • Patients with Traumatic wounds
- • Patients must be willing to attend visits as per schedule in protocol
- Exclusion criteria:
- • Patients with known allergies to any of the materials used in the dressing
- • Patients who require any oxidising agents such as hydrogen peroxide or hypochlorite solutions.
- • Patients, who in the opinion of the investigator, is considered unsuitable for any other reason
- • Patients with wounds showing signs of infection on presentation or not resolving with the use of antibiotics
About Convatec Inc.
ConvaTec Inc. is a global medical technology company dedicated to the development and commercialization of innovative products and solutions for the management of chronic and acute medical conditions. With a focus on advanced wound care, ostomy care, continence and critical care, and infusion devices, ConvaTec aims to enhance the quality of life for patients through evidence-based practices and cutting-edge research. The company is committed to clinical excellence and actively sponsors clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of healthcare delivery and patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Kerem Ozer, MD
Study Chair
Medical Director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials